AGY — Allergy Therapeutics Share News
0.000.00%
Last trade - 00:00- £369.40m
- £392.24m
- £55.20m
REG - Allergy Therapeutics - G308 Phase III Year 2 Patient Screening Starts
AnnouncementREG - Allergy Therapeutics - Warrant Exercise and Paydown of Debt
AnnouncementREG - Allergy Therapeutics - Further progress in Phase I/IIa PROTECT trial
AnnouncementRCS - Allergy Therapeutics - Grass MATA MPL Publications in Allergy Journal
AnnouncementREG - Allergy Therapeutics - Trading update for the year ended 30 June 2025
AnnouncementREG - Allergy Therapeutics - PDMR Dealings
AnnouncementRCS - Allergy Therapeutics - Allergy Therapeutics presents findings at EAACI
AnnouncementRCS - Allergy Therapeutics - EAACI Early Career Research Award
AnnouncementREG - Allergy Therapeutics - Interim Results for six months ended 31 Dec 2024
AnnouncementREG - Allergy Therapeutics - Advancement to final phase of PROTECT trial
AnnouncementREG - Allergy Therapeutics - New Executive Long Term Incentive Awards
AnnouncementRCS - Allergy Therapeutics - Presentations at 2025 AAAAI / WAO Joint Congress
AnnouncementREG - Allergy Therapeutics - Grass MATA MPL Phase III data published in Allergy
AnnouncementREG - Allergy Therapeutics - Grant of Options
AnnouncementREG - Allergy Therapeutics - Half Year Trading update
AnnouncementREG - Allergy Therapeutics - PDMR Dealing and Total Voting Rights
AnnouncementREG - Allergy Therapeutics - Director/PDMR Shareholding
AnnouncementREG - AIM - AIM Notice - 27/12/2024
AnnouncementREG - Allergy Therapeutics - Exercise of Options and Total Voting Rights
Announcement